MRI safety; Nephrogenic systemic fibrosis and other risks

Journal of Clinical Neuroscience

Volumn 17, Issue 9, 2010, Pages 1097-1104

  Gauden, Andrew J ^a   Phal, Pramit M ^a   Drummond, Katharine J ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Devices; Implants; MRI; Nephrogenic systemic fibrosis (NSF); Neurosurgery; Risks; Safety

Indexed keywords

CONTRAST MEDIUM; FERROMAGNETIC MATERIAL; GADODIAMIDE; GADOLINIUM; IMATINIB; IMMUNOSUPPRESSIVE AGENT; IODINE; PENTOXIFYLLINE; PHOTOSENSITIZING AGENT; RECOMBINANT ERYTHROPOIETIN; SODIUM THIOSULFATE;

ANAPHYLAXIS; ANEURYSM CLIP; BLOOD CLOTTING TEST; BLOOD EXAMINATION; BREAST FEEDING; CELLULITIS; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRACORPOREAL PHOTOPHERESIS; FOREIGN BODY; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; IMPLANT; KIDNEY DYSFUNCTION; LIVER FUNCTION TEST; METABOLIC ACIDOSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATIENT SAFETY; PERITONEAL DIALYSIS; PLASMAPHERESIS; PREGNANCY; PRIORITY JOURNAL; PRURITUS; PUVA; RADIATION HAZARD; REVIEW; RISK FACTOR; RISK REDUCTION; SKIN BIOPSY; SKIN REDNESS; SWELLING; SYMPTOM; SYSTEMIC SCLEROSIS; THROMBOSIS; UREA NITROGEN BLOOD LEVEL;

HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS;

EID: 77955552720     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2010.01.016     Document Type: Review

References (128)

1. A. Li, C. Wong, and M. Wong Acute adverse reactions to magnetic resonance contrast media - gadolinium chelates Br J Radiol 79 2006 368 371
2. S. Cowper, H. Robin, and S. Steinberg Scleromyxoedema-like cutaneous diseases in renal dialysis patients Lancet 356 2000 1000 1001
3. S. Cowper Nephrogenic fibrosing dermopathy: the first 6 years Curr Opin Rheumatol 15 2003 785 790
4. S. Swaminathan, and S. Shah New insights into nephrogenic systemic fibrosis J Am Soc Nephrol 18 2007 2636 2643
5. M. Sanchez-Ross, R. Snyder, and M. Colome-Grimmer Nephrogenic fibrosing dermopathy in a patient with systemic lupus erythematosus and acute lupus nephritis Pediatr Dermatol 24 2007 E36 E39
6. E. Knopp, and S. Cowper Nephrogenic systemic fibrosis: early recognition and treatment Semin Dial 21 2008 123 128
7. B. Streams, V. Liu, and N. Liegeois Clinical and pathological features of nephrogenic fibrosing dermopathy: a report of two cases J Am Acad Dermatol 48 2003 42 47
8. S. Gibson, C. Farver, and R. Prayson Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature Arch Pathol Lab Med 130 2006 209 212
9. S. Keyrouz, and S. Rudnicki Neuromuscular involvement in nephrogenic systemic fibrosis J Clin Neuromuscul Dis 9 2007 297 302
10. W. Ting, M. Stone, and K. Madison Nephrogenic fibrosing dermopathy with systemic involvement Arch Dermatol 139 2003 903 909
11. F. Mendoza, C. Artlett, and N. Sandorfi Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature Semin Arthritis Rheum 35 2006 238 249
12. C. Kucher, and S. Cowper Nephrogenic systemic fibrosis: a prototype fibrocyte disease R. Bucala, Fibrocytes: new insights into tissue repair and systemic fibrosis 2007 World Scientific Publishers Singapore 195 225
13. S. Cowper, L. Su, and J. Bhawan Nephrogenic fibrosisng dermopaty Am J Dermatopathol 23 2001 383 393
14. S. Cowper, and R. Bucala Nephrogenic fibrosing dermopathy: suspect identified, motive unclear Am J Dermatopathol 25 2003 358
15. Y. Lim, H. Lee, and S. Low Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature Clin Experiment Dermatol 32 2007 353 358
16. F. Shellock, and A. Spinazzi MRI safety update 2008: Part I, MRI contrast agents and nephrogenic systemic fibrosis Am J Roentgenol 191 2008 1129 1139
17. H. Thomsen, P. Marckmann, and V. Logager Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents Cancer Imaging 7 2007 130 137
18. A. Boyd, and J. Zic Gadolinium deposition in nephrogenic fibrosing dermopathy J Am Acad Dermatol 56 2007 27 30
19. W. High, R. Ayers, and J. Chandler Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis J Am Acad Dermatol 56 2007 21 26 (Pubitemid 46017000)
20. P. Dawson, and S. Punwani Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients Semin Dial 21 2008 160 165
21. S. Cowper, and P. Boyer Nephrogenic systemic fibrosis: an update Curr Rheumatol Rep 8 2006 151 157
22. Prevention CfDCa. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 2007;56:137-41.
23. D. Broome, M. Girguis, and P. Baron Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned Am J Roentgenol 188 2007 586 592
24. T. Collidge, P. Thomson, and P. Mark Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort Radiology 245 2007 168 175
25. T. Grobner Gadolinium: a specific trigger for the development of nephrogenic systemic dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 2006 1104 1108
26. P. Marckmann, L. Skov, and K. Rossen Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
27. T.G.F. Prischl Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure Sem Dial 21 2008 135 139
28. P. Marckmann, L. Skov, and K. Rossen Case-control study of gadodiamide-related nephrogenic systemic fibrosis Nephrol Dial Transplant 22 2007 3174 3178
29. M.R. Prince, H.L. Zhang, and G.H. Roditi Risk factors for NSF: a literature review J Magn Reson Imaging 30 2009 1298 1308
30. P. Marckmann, L. Skov, and K. Rossen Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging J Am Soc Nephrol 17 2006 2359 2362
31. P. Marckmann, L. Skov, and K. Rossen Case-control study of gadodiamide-related nephrogenic systemic fibrosis Nephrol Dial Transplant 2007
32. P. Leboit What nephrogenic fibrosing dermopathy might be Arch Dermatol 139 2003 928 930
33. R. Bucala Circulating fibrocytes: cellular basis for NSF J Am Coll Radiol 5 2008 36 39
34. A. Auron, L. Shao, and B. Warady Nephrogenic fibrosing dermopathy in children Pediatr Dermatol 21 2006 1307 1311
35. F. Jan, J. Segal, and J. Dyer Nephrogenic fibrosing dermopathy: two pediatric cases J Pediatr 143 2003 678 681
36. P. Yerram, G. Saab, and P. Karuparthi Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate Clin J Am Soc Nephrol 2 2007 258 263
37. I.A. Mendichovszky, S.D. Marks, and C.M. Simcock Gadolinium and nephrogenic systemic fibrosis: time to tighten practice Pediatr Radiol 38 2008 489 496
38. D. Linfert, J. Schell, and D. Fine Treatment of nephrogenic systemic fibrosis: limited options but hope for the future Semin Dial 21 2008 155 159
39. S. Lauchli, C. Zortea-Caflisch, and F. Nestle Nephrogenic fibrosing dermopathy treated with extracorporeal photophoresis Dermatology 208 2004 278 280
40. J. Mackay-Wiggan, D. Cohen, and M. Hardy Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease) J Am Acad Dermatol 48 2003 55 60
41. H. Richmond, J. Zwerner, and Y. Kim Nephrogenic systemic fibrosis: relationship to GBC and response to photophoresis Arch Dermatol 143 2007 1025 1030
42. R. Swartz, L. Crofford, and S. Phan Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure Am J Med 114 2003 563 572
43. R. Rodby Dialytic therapies to prevent NSF following gadolinium exposure in high risk patients Semin Dial 21 2008 145 149
44. K.T. Tran, H.B. Prather, and C.J. Cockerell UV-A1 therapy for nephrogenic systemic fibrosis Arch Dermatol 145 2009 1170 1174
45. T. Schmook, K. Budde, and C. Ulrich Successful treatment of nephrogenic fibrosing dermopathy in a kidney transplant recipient with photodynamic therapy Nephrol Dial Transplant 20 2005
46. J. Kay, and W. High Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis Rheum 58 2008 2543 2548
47. S. Tishler, and J. Hoffman Anaphylactoid reactions to i.v. gadopentetate dimeglumine Am J Neuroradiol 11 1990 1167 1169
48. B. Tardy, C. Guy, and G. Barral Anaphylactic shock induced by intravenous gadopentetate dimeglumine Lancet 339 1992 494
49. H. Sahni, P. Jayakumar, and R. Lalla Anaphylactoid reaction following intravenous gadolinium dimeglumine - a case report Ind J Radiol Imaging 12 2002 81 82
50. K. Murphy, J. Brunberg, and R. Cohan Adverse reactions to gadolinium contrast media: a review of 36 cases AJR Am J Roentgenol 10 1996 641 648
51. J. Caro, E. Trindade, and M. McGregor The cost-effectiveness of replacing high-osmolarity with low-osmolarity contrast media AJR Am J Roentgenol 159 1992 869 874
52. F. Shellock, and J. Crues MR procedures: biologic effects, safety, and patient care Radiology 232 2004 635 652
53. F. Shellock, and A. Spinazzi MRI safety update 2008: Part 2, screening patients for MRI AJR Am J Roentgenol 191 2008 1140 1149
54. F. Shellock Magnetic resonance bioeffects, safety, and patient management R. Edelman, J. Hesselink, M. Zlatkin, Clinical magnetic resonance imaging 3rd ed. 2005 Saunders Philadelphia, PA 680 733
55. F. Shellock Reference manual for magnetic resonance safety, implants, and devices 2008 Biomedical Research Publishing Group Los Angeles, CA
56. F. Shellock Magnetic resonance procedure: health effects and safety 2001 CRC Press Boca Raton, FL
57. Shellock F. MRIsafety.com: MRI safety, bioeffects and patient management. < www.mrisafety.com >; [02.2009; cited 02.2009]
58. F. Shellock Magnetic resonance procedures and aneurysm clips: A review Signals 33 2000 17 20
59. M. Brown, J. Carden, and R. Coleman Magnetic field effects on surgical ligation clips Magn Reson Imaging 5 1987 443 453
60. M. Dujovny, N. Kossovsky, and R. Kossowsky Aneurysm clip motion during magnetic resonance imaging: in vivo experimental study with metallurgical factor analysis Neurosurgery 17 1985 543 548
61. K. Go, R. Kamman, and E. Mooyart Interaction of metallic neurosurgical implants with magnetic resonance imaging at 1.5 Tesla as a cause of image distortion and hazardous movement of the implant Clin Neurosurg 91 1989 109 115
62. F. Shellock, S. Morisoli, and E. Kanal MR procedures and biomedical implants, materials, and devices: 1993 update Radiology 189 1993 587 599
63. R. Klucznik, D. Carrier, and R. Pyka Placement of a ferromagnetic intracerebral aneurysm clip in a magnetic field with a fatal outcome Radiology 187 1993 855 856
64. F. Shellock, and V. Shellock MR-compatibility evaluation of the Spetzler titanium aneurysm clip Radiology 206 1998 838 841
65. F. Shellock, and E. Kanal Yasargil aneurysm clips: evaluation of interactions with a 1.5-Tesla MR system Radiology 206 1998 587 591
66. F. Shellock Biomedical implants and devices: assessment of magnetic field interactions with a 3.0-Tesla MR system J Magn Reson Imaging 16 2002 721 732
67. F. Shellock, J. Tkach, and P. Ruggieri Aneurysm clips: evaluation of magnetic field interactions and translational attraction using "long-bore" and "short-bore" 3.0-Tesla MR systems Am J Neuroradiol 24 2003 463 471
68. C. Hennemeyer, K. Wicklow, and D. Feinberg In vitro evaluation of platinum Guglielmi detachable coils at 3-T with a porcine model: safety issues and artifacts Radiology 219 2001 732 737
69. F. Shellock, M. Detrick, and M. Brant-Zawadski MR-compatibility of the Guglielmi detachable coils Radiology 203 1997 568 570
70. T. Inoue, Y. Kuzu, and K. Ogasawara Effect of 3-Tesla magnetic resonance imaging on various pressure programmable shunt valves J Neurosurg 103 Suppl. 2 2005 163 165
71. F. Shellock, S. Wilson, and C. Mauge Magnetically programmable shunt valve: MRI at 3-Tesla Magn Reson Imaging 25 2007 1116 1121
72. F. Shellock, R. Habibi, and J. Knebel Programmable CSF shunt valve: in vitro assessment of MR imaging safety at 3T AJNR Am J Neuroradiol 27 2006 661 665
73. E. Kanal, J. Borgstede, and A. Barkovich American college of radiology white paper on MR safety, 2004 update and revisions Am J Radiol 182 2004 1111 1114
74. G. Levine, A. Gomes, and A. Arai Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance Circulation 116 2007 2878 2891
75. J. Shinbane, P. Colletti, and F. Shellock MR in patients with pacemakers and ICDs: defining the issues J Cardiovasc Magn Reson 9 2007 5 13
76. J.L. Del Ojo, F. Moya, and J. Villalba Is magnetic resonance imaging safe in cardiac pacemaker recipients? Pace 28 2005 274 278
77. W. Kelly, P. Pagle, and A. Pearson Ferromagnetism of intraocular foreign body causes unilateral blindness after MR study Am J Neuroradiol 7 1986 243
78. D. Seidenwurm, C. McDonnell, and N. Raghavan Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging Am J Neuroradiol 21 2000 426
79. F. Shellock, and E. Kanal Bioeffects and safety of MR procedures R. Edelman, J. Hesselink, M. Zlatkin, Clinical magnetic resonance imaging 1996 W.B. Saunders Philadelphia 429
80. D. Levine Obstetric MRI J Magn Reson Imaging 24 2006 1 15
81. J. Webb, H. Thomsen, and S. Morcos The use of iodinated and gadolinium contrast media during pregnancy and lactation Eur Radiol 15 2005 1234 1240
82. R. Kubik-Huch, N.G. Alama, and T. Frenzel Gadopentate dimeglumine excretion into human breast milk during lactation Radiology 216 2000 555 558
83. U. Shmiedl, K. Maravilla, and R. Gerlach Excretion of gadopentate dimeglumine in human breast milk Am J Roentgenol 154 1990 1305 1306
84. N. Rofsky, J. Weinreb, and A. Litt Quantitative analysis of gadopentate dimeglumine excreted in breast milk J Magn Reson Imaging 3 1993 131 132
85. L. Marti-Bonmati, T. Vega, and C. Benito Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study Invest Radiol 35 2000 141 147
86. B. Tsai-Goodman, T. Geva, and K. Odegard Clinical role, accuracy and technical aspects of cardiovascular magnetic resonance imaging in infants Am J Cardiol 94 2004 69 74
87. M. Laniado, W. Kommesser, and B. Hamm MR imaging of the gastrointestinal tract: value of Gd-DTPA Am J Roentgenol 150 1988 817 821
88. E. Sadowski, L. Bennett, and M. CHan Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 2007 148 157
89. R. Nowack, and P. Wachtler Scleroderma-like syndrome triggered by gadolinium Nephrol Dial Transplant 21 2006 3344
90. S. Jain, S. Wesson, and A. Hassanein Nephrogenic fibrosing dermopathy in pediatric patients Pediatr Nephrol 19 2004 467 470
91. V. Dharnidharka, S. Wesson, and R. Fennell Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients Pediatr Nephrol 22 2007 1395
92. A. Deo, M. Fogel, and S. Cowper Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure Clin J Am Soc Nephrol 2 2007 264 267
93. J. Pryor, G. Poggioli, and N. Galaria Nephrogenic systemic fibrosis: a clinicopathologic study of six cases J Am Acad Dermatol 57 2007 105 111 (Pubitemid 46899273)
94. J. Pryor, and G. Scott Nephrogenic systemic fibrosis: a clinicopathologic study of 6 cases J Am Acad Dermatol 57 2007 902 903 (Pubitemid 47553084)
95. P. Cheung, and A.D. Raj Nephrogenic fibrosing dermopathy: a new clinical entity mimicking scleroderma Intern Med J 37 2007 139 141
96. J. Moreno-Romero, S. Segura, and J. Mascaro Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor BR J Dermatol 157 2007 783 787
97. V. Garovic, and K. Helgen Nephrogenic fibrosing dermopathy N Engl J Med 357 2007 e2
98. K. Hamilton-Persaud, L. Ezell, and J. Macklin Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis Nephrol Nurs J 34 2007 283 287
99. C. Thakral, J. Alhariri, and J. Abraham Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications Contrast Media Mol Imaging 2 2007 199 205
100. J. Othersen, J. Maize, and R. Woolson Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure Nephrol Dial Transplant 22 2007 3179 3185
101. D. Todd, A. Kagan, and L. Chibnik Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure Arthritis Rheum 56 2007 3433 3441
102. H. Pieringer, B. Schmekal, and O. Janko Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis Nephrol Dial Transplant 22 2007 3094
103. H. Krous, E. Breisch, and A. Chadwick Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis Pediatr Dev Pathol 10 2007 395 402
104. M. Khurram Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients Scand J Urol Nephrol 41 2007 565 566
105. T. Launstein, K. Salman, and R. Morreira Nephrogenic systemic fibrosis: center case review J Magn Reson Imaging 26 2007 1198 1203
106. D. Martin Nephrogenic systemic fibrosis Pediatr Radiol 38 Suppl. 1 2008 s125 s129
107. C. Tsai, C. Chao, and V. Wu Nephrogenic fibrosing dermopathy in a peritoneal dialysis patient Kidney Int 72 2007 1294
108. R. Kalb, T. Helm, and H. Sperry Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury Br J Dermatol 158 2008 607 610
109. E. Naylor, S. Hu, and L. Robinson-Bostom Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum J Am Acad Dermatol 58 2008 149 150
110. T. Caccetta, and J. Chan Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium Australas J Dermatol 49 2008 48 51
111. G. Kane, A. Stanson, and D. Kalnicka Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes Nephrol Dial Transplant 23 2008 1233 1240
112. A. Dhungel, R. Lattupalli, and J. Topf Nephrogenic fibrosing dermopathy Scientific World J 6 2008 164 165
113. W. Shabana, R. Cohen, and J. Ellis Nephrogenic systemic fibrosis: a report of 29 cases Am J Roentgenol 190 2008 736 741
114. R. Christiansen, L. Sviland, and I. Skese Nefrogen systemisk fibrose ved bruk av MR-kontrastmiddel Tidsskr Nor Laegeforen 129 2009 180 182
115. D. Kadiyala, D. Roer, and M. Perazella Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate Am J Kidney Dis 53 2009 133 137
116. S. Chandran, J. Petersen, and C. Jacobs Imatinib in the treatment of nephrogenic systemic fibrosis Am J Kidney Dis 53 2009 129 132
117. Y. Nagai, M. Hasegawa, and K. Shinmi Nephrogenic systemic fibrosis with multiple calcification and osseous metaplasia Acta Derm Venereol 88 2008 597 600
118. K. Shin, S. Granter, and J. Coblyn Progressive arm and leg stiffness in a patient with chronic renal impairment Nat Clin Pract Rheumatol 4 2008 557 562
119. K. Duffy, L. Green, and R. Harris Treatment of nephrogenic systemic fibrosis with Re-PUVA J Am Acad Dermatol 59 Suppl. 1 2008 s39 s40
120. K. Mathur, S. Morris, and C. Deighan Extracorporeal photopheresis improves nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: three case reports and review of literature J Clin Apher 23 2008 144 150
121. C. Introcaso, R. Elentisas, and X. Xu Periocular papules in nephrogenic systemic fibrosis J Am Acad Dermatol 59 2008 536 537
122. S. Grebe, M. Borrmann, and A. Altenburg Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure Clin Exp Nephrol 12 2008 403 406
123. P. Marckmann, A. Nielsen, and J. Sloth Possibly enhanced Gd excretion in dialysate, but no major clinical benefit of 3-5 months of treatment with sodium thiosulfate in late stages of nephrogenic systemic fibrosis Nephrol Dial Transplant 23 2008 3280 3282
124. C. Chao, C. Yang, and C. Hsiao Nephrogenic systemic fibrosis associated with gadolinium use J Formos Med Assoc 107 2008 270 274
125. J. Schroeder, C. Weingart, and B. Coras Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease Clin J Am Soc Nephrol 3 2008 968 995
126. J. Wigle, and D. Broome Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature Skeletal Radiol 37 2008 457 464
127. S. Digby, E. Macduff, and K. Blessing Nephrogenic systemic fibrosis: a histopathological study of eight cases of a recently described entity Histopathology 52 2008 531 534
128. N. Anavekar, A. Chong, and R. Norris Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient Australas J Dermatol 49 2008 44 47